Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

New EU Approvals

Executive Summary

The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Upstaza, PTC Therapeutics’ disease-modifying gene therapy for children with the fatal, rare genetic disorder, AADC deficiency.

You may also be interested in...



Advanced Therapy Developers Urged To Monitor Major EU Proposal On Using Blood, Tissues & Cells

Companies have the opportunity to tell the European Commission what they think about its proposed regulation that would overhaul the rules governing the use of substances of human origin.

Accelerated Assessment Dry Spell Over As EMA Says Yes To Pharming’s Leniolisib

Leniolisib has become the first product to be granted accelerated assessment status by the European Medicines Agency this year.

Rhythm Wins Reimbursement For Obesity Drug Imcivree In France & England

France is set to become the first country in Europe to fund Imcivree for a second – and as yet unapproved – indication. Meanwhile, England has agreed to reimburse the drug for its approved indication as did Germany earlier this year. Reimbursement discussions are underway in the rest of Europe.

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS146793

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel